News & Events

Press releases

Pneumagen Presents Positive Phase 2 Influenza Human Challenge Study data on Neumifil, its Broad-Spectrum Antiviral Drug, at the American Thoracic Society (ATS) 2024 Conference

READ MORE...

Pneumagen to Present Phase 2 Clinical Data on Neumifil, its Broad-Spectrum Antiviral, Intranasal Drug for Viral Respiratory Tract Infections, at ATS 2024

READ MORE...

Pneumagen Announces Successful Clinical Proof of Concept for its Broad-Spectrum Antiviral Neumifil in Phase 2 Influenza Human Challenge Study

READ MORE...

Pneumagen raises £8m to accelerate Phase 2 clinical development of Neumifil for the prevention & treatment of viral respiratory tract infections

READ MORE...

Pneumagen further strengthens IP protection for lead product Neumifil with granting of US composition of matter patent

READ MORE...

Pneumagen appoints James Noble, a highly experienced biotech leader, as Chairman of its Board of Directors

READ MORE...

Pneumagen Creates International Clinical Advisory Group of World Leading Respiratory and Infectious Disease Experts

READ MORE...

Pneumagen Announces First Patient Dosed in Phase 2 Proof of Concept Influenza Challenge Study Assessing Neumifil, an Intranasal Broad-Spectrum Antiviral

READ MORE...

Pneumagen Announces Positive Top Line Results from Phase 1 Study Evaluating Neumifil, a Product Designed for the Prevention and Treatment of Viral Respiratory Tract Infections

READ MORE...

Event information

Jefferies London Healthcare Conference | November 15th – 17th 2022

READ MORE...

BIO-Europe in Leipzig | October 24th – 26th 2022

READ MORE...

BIO International Convention in San Diego | June 13th – 16th 2022

READ MORE...

Bio€quity Europe in Milan | May 16th – 18th 2022

READ MORE...

BioTrinity 2022 in London | April 26th – 27th 2022

READ MORE...

BIO-Europe Spring Digital | March 28th – 30th 2022

READ MORE...